MBX Biosciences, Inc. Common Stock (MBX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism.
Is MBX Biosciences, Inc. Common Stock stock overvalued or undervalued in 2026?
As of November 3, 2026, MBX Biosciences, Inc. Common Stock (MBX) trades at $55.00 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: MBX Biosciences, Inc. Common Stock
Market cap $3B · 52 weeks $21 – $71 (23 % below the high) · P/E no earnings · Dividend none · Next earnings November 5, 2026 · expected EPS -$0.83 · Closing price, Nov 3 · accounts published Aug 6.
- Valuation: P/E — (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 6 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 5.4×, fails.
- Cash Runway 56 months, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $2.19, info.
Against its peers (reference peers) — MBX Biosciences, Inc. Common Stock: P/E —; EV/EBITDA —; ROIC -28.6 %; $2.6B. Ascendis Pharma A/S (P/E 18.5×; EV/EBITDA 183×; ROIC 5.8 %; $16.5B), ADMA Biologics, Inc. (P/E 15.9×; EV/EBITDA 10.9×; ROIC 27.6 %; $2.5B), Nurix Therapeutics, Inc. (P/E 11.2×; EV/EBITDA 6.7×; ROIC 25.9 %; $2.8B).
Profitability
| Return on Equity | -26.01% |
| Return on Invested Capital | -28.56% |
| Return on Assets | -23.93% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 18.08 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 42.88 |
Price Performance
| 1 month | -7.07% |
| 3 months | -18.94% |
| Year-to-date | +72.48% |
| 1 year | +163.82% |
Related companies: ASND · RYTM · VKTX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of MBX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks